HDT Global specializes in developing innovative gene therapies using adeno-associated viral (AAV) vectors, aiming to transform treatment for a range of diseases. We cater to the biotech and pharmaceutical industries, providing cutting-edge solutions that harness the power of gene editing and therapy.
